Tocilizumab

mAbs

Volumn 1, Issue 5, 2009, Pages 432-438

  Venkiteshwaran, Adith ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Castleman's disease; Crohn's disease; IL 6 receptor; Interleukins for rheumatoid arthritis; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ADALIMUMAB; ATLIZUMAB; AZATHIOPRINE; CHLOROQUINE; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; ROACTEMRA; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; RHEUMATOID ARTHRITIS; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG ADMINISTRATION; EUROPEAN UNION; IMMUNOLOGY; JAPAN; MOUSE; REVIEW; TREATMENT OUTCOME; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; EUROPEAN UNION; GIANT LYMPH NODE HYPERPLASIA; HUMANS; JAPAN; MICE; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME; UNITED STATES;

EID: 77950342734     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.5.9497     Document Type: Short Survey

References (22)

1. Strand V, Kimberly R, Isaacs J. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Disc 2007; 6:75-92. (Pubitemid 46020288)
2. Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 2001; 19:163-196
3. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R downregulation of Type II collagen, aggrecan core and link protein transcription in articular chondrocytes: association with a downregulation of SOX9 expression. J Biol Chem 2003; 278:2903-2912 (Pubitemid 36801195)
4. De Hooge AS, van de Loo FA, Arntz OJ, van den Berg WB. Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol 2000; 157:2081-2091
5. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNFα, IL-1 and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004; 114:582-588 (Pubitemid 39572108)
6. Melton L, Coombs A. Actemra poised to launch IL-6 inhibitors. Nat Biotechnol 2008; 26:957-959
7. Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P. Fresh from the Pipeline: Tocilizumab. Nature Reviews Drug Discovery 2009; 8:273-274
8. Smolen JS, Beaulieu A, Rubbert Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:989-997
9. Genovese M, McKay J, Nasonov E, Mysler E, Da Silva N, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2008; 58:2968-2980
10. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67:1516-1523 RADIATE study.
11. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2009; [Epub ahead of print].
12. Kremer JM, Fleischmann RM, Halland A, Brzezicki J, Woodworth T, Fisheleva E, et al Tocilizumab inhibits structural joint damage in RA patients with an inadequate response to methotrexate: The LITHE study. American College of Rheumatology Annual Meeting 2008; Oct 25-28, San Francisco; abs L14. http://acr.confex.com/acr/2008/webprogram/Paper3479.html.
13. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66:1162-1167 (Pubitemid 47309731)
14. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19:12-19
15. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008; [Epub ahead of print].
16. http://clinicaltrials.gov/ct2/results?term=TOCILIZUMAB&pg = 1.
17. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371:998-1006.
18. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000; 95:56-61. (Pubitemid 30017224)
19. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106:2627-2632 (Pubitemid 41510733)
20. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterol 2004; 126:989-996 (Pubitemid 38451170)
21. Korzenik J, Podolsky D. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Disc 2006; 5:197-209. (Pubitemid 43336033)
22. Agrawal S. What's fueling the biotech engine? Nat Biotech 2007; 25:1094-1107